Novel Gyrase Mutations in Quinolone-Resistant and -Hypersusceptible Clinical Isolates of Mycobacterium tuberculosis : Functional Analysis of Mutant Enzymes
Open Access
- 1 January 2006
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 50 (1) , 104-112
- https://doi.org/10.1128/aac.50.1.104-112.2006
Abstract
Mutations in the DNA gyrase GyrA 2 GyrB 2 complex are associated with resistance to quinolones in Mycobacterium tuberculosis . As fluoroquinolones are being used increasingly in the treatment of tuberculosis, we characterized several multidrug-resistant clinical isolates of M. tuberculosis carrying mutations in the genes encoding the GyrA or GyrB subunits associated with quinolone resistance or hypersusceptibility. In addition to the reported putative quinolone resistance mutations in GyrA, i.e., A90V, D94G, and D94H, we found that the GyrB N510D mutation was also associated with ofloxacin resistance. Surprisingly, several isolates bearing a novel combination of gyrA T80A and A90G changes were hypersusceptible to ofloxacin. M. tuberculosis GyrA and GyrB subunits (wild type [WT] and mutants) were overexpressed in Escherichia coli , purified to homogeneity, and used to reconstitute highly active gyrase complexes. Mutant proteins were produced similarly from engineered gyrA and gyrB alleles by mutagenesis. MICs, enzyme inhibition, and drug-induced DNA cleavage were determined for moxifloxacin, gatifloxacin, ofloxacin, levofloxacin, and enoxacin. Mutant gyrase complexes bearing GyrA A90V, D94G, and D94H and GyrB N510D were resistant to quinolone inhibition (MICs and 50% inhibitory concentrations [IC 50 s] at least 3.5-fold higher than the concentrations for the WT), and all, except the GyrB mutant, were less efficiently trapped as a quinolone cleavage complex. In marked contrast, gyrase complexes bearing GyrA T80A or A90G were hypersusceptible to the action of many quinolones, an effect that was reinforced for complexes bearing both mutations (MICs and IC 50 s up to 14-fold lower than the values for the WT). This is the first detailed enzymatic analysis of hypersusceptibility and resistance in M. tuberculosis .Keywords
This publication has 37 references indexed in Scilit:
- Fluoroquinolone Susceptibility among Mycobacterium tuberculosis Isolates from the United States and CanadaClinical Infectious Diseases, 2005
- Multiplex PCR Amplimer Conformation Analysis for Rapid Detection of gyrA Mutations in Fluoroquinolone-Resistant Mycobacterium tuberculosis Clinical IsolatesAntimicrobial Agents and Chemotherapy, 2004
- Identification of Mycobacterial Species by PCR Sequencing of Quinolone Resistance-Determining Regions of DNA Gyrase GenesJournal of Clinical Microbiology, 2003
- Molecular Characterization of Multidrug-Resistant Isolates of Mycobacterium tuberculosis from Patients in North IndiaAntimicrobial Agents and Chemotherapy, 2002
- DNA Topoisomerases: Structure, Function, and MechanismAnnual Review of Biochemistry, 2001
- The Complex of DNA Gyrase and Quinolone Drugs on DNA Forms a Barrier to the T7 DNA Polymerase Replication ComplexJournal of Molecular Biology, 2000
- Selection of Antibiotic?Resistant Bacterial Mutants: Allelic Diversity among Fluoroquinolone?Resistant MutationsThe Journal of Infectious Diseases, 2000
- Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequenceNature, 1998
- The Complex of DNA Gyrase and Quinolone Drugs with DNA Forms a Barrier to Transcription by RNA PolymeraseJournal of Molecular Biology, 1994
- Selection of a gyrA Mutant of Mycobacterium tuberculosis Resistant to Fluoroquinolones during Treatment with OfloxacinThe Journal of Infectious Diseases, 1994